logo
A Wedding Season Skincare Essential

A Wedding Season Skincare Essential

Living in New York City (and attending all those aforementioned weddings), I'm tough on my feet. I walk just about everywhere, often in shoes that aren't necessarily made for trekking long distances. I can put up with a little soreness here and there, and I try to avoid blisters at all costs with strategically placed bandages, but my less-than-gentle treatment of my feet has led to dry skin and cracked heels. And whether I'm wearing strappy sandals at a wedding or going barefoot in a yoga class, it can be both uncomfortable and a little embarrassing.
Luckily, the Pedestrian Project balm works quickly. I first tried it out a few days ahead of traveling to Arizona for a wedding. I was impressed with how soft my previously dry heels felt after two days of applying the balm morning and night. My skin stayed smooth and resisted cracking even in dry, unseasonably-warm-for-April 100-degree heat. Since then, it's become a permanent fixture in my nighttime routine.
How does it work?
The balm is made with a blend of mango butter and candelilla wax to lock in moisture, as well as African shea butter to soften skin. It glides effortlessly onto heels, toes or anywhere you could use a little extra hydration—the texture feels thick and butter-like. The formula also includes black currant seed oil, which is anti-inflammatory, and vitamin E to soothe inflamed or itchy skin. The scent is lovely, somewhere between lightly citrusy and herbal, but not overpowering.
I still get calluses and dry patches occasionally, but when I do, the balm swiftly comes to the rescue. And while it works well on its own, I find it's even more effective after I exfoliate with Soft Services' Buffing Bar, or for extra-tough calluses, a foot file, like this one from Dr. Scholl's.
The balm also solves my main issue with other footcare products that come in tubes or tubs—it's not messy. All I have to do is apply the balm with its handy stick applicator and slip on a pair of socks. I don't even have to touch my feet (not that I would mind, since the product isn't greasy in the slightest). In the morning, I wake up with smoother skin than I thought was possible.
Ideally, I'd love to get a fresh pedicure ahead of every formal event I attend, but if time doesn't allow for an appointment and I'm left to DIY at home, Pedestrian Project's balm comes in handy every time. It may not help soothe sore feet after dancing all night (I'm still on the hunt for that miracle product), but at least my skin is smooth, soft and comfortable as ever.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Myosin Therapeutics Awarded $4.5 Million NCI Bridge Grant to Advance Phase I Trial of MT-125 in Glioblastoma
Myosin Therapeutics Awarded $4.5 Million NCI Bridge Grant to Advance Phase I Trial of MT-125 in Glioblastoma

Yahoo

time27 minutes ago

  • Yahoo

Myosin Therapeutics Awarded $4.5 Million NCI Bridge Grant to Advance Phase I Trial of MT-125 in Glioblastoma

JUPITER, Fla., Aug. 19, 2025 /PRNewswire/ -- Myosin Therapeutics, a biotechnology company developing novel therapies for aggressive cancers, today announced it has been awarded a $4.5M Phase IIB Bridge Award from the National Cancer Institute's (NCI) Small Business Innovation Research (SBIR) program. The funding will support Myosin Therapeutic's Phase I STAR-GBM dose escalation and expansion trial of MT-125, a first-in-class novel small molecule therapeutic being evaluated in patients with newly diagnosed, MGMT unmethylated glioblastoma. Glioblastoma remains among the most lethal cancers, with median survival measured in months. MT-125 targets non-muscle myosin II, a critical driver of tumor cell invasion, proliferation and treatment resistance, representing a novel therapeutic approach that is distinct from existing standards of care. The STAR-GBM trial will assess the safety, tolerability, and pharmacokinetics of MT-125 in this patient population with significant unmet need. Exploratory endpoints include measures of efficacy, including progression-free survival and overall survival. The NCI SBIR program is one of the most competitive federal funding mechanisms for cancer-focused innovation, providing support to small businesses with technologies that have strong scientific merit, commercial potential, and a clear path to clinical impact. Bridge Awards, which require that matching funds from private capital be raised first, are reserved for companies with promising, later-stage projects that have already demonstrated significant technical progress and the potential to attract substantial private investment. "The NCI Bridge Award was perfectly timed to support our STAR-GBM trial, for which patient enrollment is set to begin in November," said Dr. Courtney Miller, co-founder and CEO of Myosin Therapeutics. "It will enable us to generate the data needed to position the program for later-stage development, potential partnerships, and future expansion into a wider range of patients. Our ultimate goal is to deliver a transformative treatment option for patients who currently face limited or inadequate therapeutic choices." About Myosin TherapeuticsMyosin Therapeutics is a Jupiter, FL-based biotechnology company spun out of The Wertheim UF Scripps Institute (formerly Scripps Research, Florida). The company is focused on developing therapies for neuroscience and oncology indications using a platform that targets molecular nanomotor proteins. For more information, visit Contact: contact@ View original content to download multimedia: SOURCE Myosin Therapeutics Inc.

FDA Suggest Walmart Recalls Frozen Shrimp After Radiation Detected At Port
FDA Suggest Walmart Recalls Frozen Shrimp After Radiation Detected At Port

Forbes

time29 minutes ago

  • Forbes

FDA Suggest Walmart Recalls Frozen Shrimp After Radiation Detected At Port

The Food and Drug Administration is warning that some Great Value brand frozen shrimp sold at Walmart could be contaminated with radioactive isotope Cesium-137 after Customs and Border Protection detected the substance in shipping containers at four major American ports and at least one sample of shrimp. Cesium-137 was detected in some frozen shrimp coming from Indonesia—but none that have been sold in stores yet. getty The FDA is investigating the potential contamination and has not 'confirmed the presence of contamination in any product in commerce,' they are still warning consumers to avoid eating shrimp that come from the same Indonesian producer BMS Foods. The FDA is recommending Walmart recall frozen shrimp coming from BMS Foods, and the retailer has not returned a request for comment from Forbes. This is a breaking story and will be updated.

Medical group goes against CDC, recommend COVID shots for young kids
Medical group goes against CDC, recommend COVID shots for young kids

Fox News

timean hour ago

  • Fox News

Medical group goes against CDC, recommend COVID shots for young kids

The Centers for Disease Control and Prevention (CDC) no longer recommends the COVID-19 vaccine for children — but a major medical group is going against that guidance. On Tuesday, the American Academy of Pediatrics (AAP) released its latest annual immunization schedule for children — and it includes vaccines for COVID-19, in addition to flu and RSV. "Infants and children 6 through 23 months of age are at the highest risk for severe COVID-19," the AAP states in its release. "Given this, the AAP recommends a COVID-19 vaccine for all children ages 6 through 23 months old to help protect against serious illness." The AAP also recommends a "single dose of age-appropriate COVID-19 vaccine" for kids and teens 2 and older who are at high risk of severe COVID, have never been vaccinated before, and who live with people who are at a high risk of severe disease. "The AAP also recommends the vaccine be available for children aged 2-18 who do not fall into these risk groups, but whose parent or guardian desires them to have the protection of the vaccine," the release states. "Among the reasons we decided to move to a risk-based recommendation for healthy older children is the fact that the hospitalization rate for young children and children with underlying medical conditions remains high, in line with rates for many of the other vaccine-preventable diseases for which we vaccinate," said Sean O'Leary, M.D., chair of the AAP Committee on Infectious Diseases, in the release. In May 2025, HHS Secretary Robert F. Kennedy Jr. announced that COVID-19 vaccines would be removed from the CDC's routine immunization schedule for healthy children and pregnant women. Instead of a universal recommendation, the CDC's updated guidance calls for "shared clinical decision-making," in which parents and doctors discuss the benefits and risks of vaccination for each individual case. "Where the parent presents with a desire for their child to be vaccinated, children 6 months and older may receive COVID-19 vaccination, informed by the clinical judgment of a healthcare provider and personal preference and circumstances," the CDC's guidance states. In total, the AAP's schedule includes immunizations against 18 diseases, recommended for all children from birth to age 18. The AAP noted in a press release that its vaccine schedule "differs from recent recommendations of the Advisory Committee on Immunization Practices of the CDC." For more Health articles, visit Other included updates involve the pentavalent meningococcal vaccine, the starting age of the human papilloma virus vaccine, and removal of a hepatitis vaccine that is no longer available, the release states.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store